Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic acid in cardiopulmonary bypass prime solution for open heart surgery bleeding reduction
IRCT20240220061056N1Phase 3Completed
- Sponsor
- Shahid Sadoughi University of Medical Sciences
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of tranexamic acid in coronary arteriosclerosis and Cardiac valve disease (VHD) (2 arms), sponsored by Shahid Sadoughi University of Medical Sciences. Primary endpoints: Amount of postoperative bleeding, Hemodynamic stability and 1 more. Started Mar 2024; status: completed.
02
Drugs
tranexamic acid
03
Conditions
coronary arteriosclerosisCardiac valve disease (VHD)
Beyond the preview
Go deeper on IRCT20240220061056N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240220061056N1.